MedTrace Logo

Titrating-Dose of Lonafarnib in Combination With Ritonavir

NCT02527707 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-06-22

Study results available
· View outcomes & findings →

Summary

A phase 2, open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic activity of titrating-dose lonafarnib/ritonavir in patients chronically infected with hepatitis delta virus (HDV)

Conditions

  • Chronic Delta Hepatitis

Interventions

DRUG

lonafarnib

antiviral farnesyltransferase inhibitor

DRUG

Ritonavir

Cytochromes P450 3A4 inhibitor used to boost lonafarnib

Sponsors & Collaborators

  • Hannover Medical School

    collaborator OTHER

  • Eiger BioPharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Heiner Wedemeyer, MD, PhD · Hannover Medical School

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2016-08-31
Completion
2017-02-09

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02527707 on ClinicalTrials.gov